Hemospan (MP4OX)

Phase 3Small molecule

SSangart

Hemospan (MP4OX) is one of 61 small molecule programs targeting Ischemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

IschemiaActive, not recruiting

HypotensionActive, not recruiting

IschemiaPhase 2

Active, not recruiting

HypotensionPhase 3

Active, not recruiting

Competition

Competitive Landscape

159 competitors in Ischemia

#DrugCompanyPhaseTrials

Adenocard

Astellas

Phase 3

3 2

Isordil

AstraZeneca

Phase 3

1 3

Osmitrol

BB. Braun Medical Inc.

Phase 3

1 4

Garamycin

SSchering-Plough

Phase 3

1 5

Procardia

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 6

Cardizem

BBausch Health Americas, Inc.

Phase 3

1 7

Flagyl

DDePuy Orthopaedics

Phase 3

1 8

Avlosulfon

AAlmirall, S.A.

Phase 3

1 9

Remodulin

United Therapeutics

Phase 3

2 10

Ixmyelocel-T

VVericel Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypotension2 trials

Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty

Completed·SSangart·Phase 3·NCT00420277·462 enrolled

Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty

Completed·SSangart·Phase 3·NCT00421200·375 enrolled

Prostatectomy1 trial

Safety Study of Hemospan® in Prostatectomy Patients

Completed·SSangart·Phase 2·NCT00425334·20 enrolled

Ischemia1 trial

Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia

Completed·SSangart·Phase 2·NCT00633659·6 enrolled

Orthopedic Surgery1 trial

Increasing Dose Safety Study of Hemospan in Orthopedic Surgery Patients

Completed·SSangart·Phase 1/2·NCT00494949·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Hemospan (MP4OX). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hemospan (MP4OX) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hemospan (MP4OX). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sangart company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSangart

Hemospan (MP4OX)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypotension2 trials

Prostatectomy1 trial

Ischemia1 trial

Orthopedic Surgery1 trial

References

Drug Info

Quick Facts

Related News